Galapagos NV Stock Euronext Bruxelles
Equities
GLPG
BE0003818359
Biotechnology & Medical Research
Sales 2024 * | 337M 362M | Sales 2025 * | 314M 337M | Capitalization | 1.8B 1.93B |
---|---|---|---|---|---|
Net income 2024 * | -44M -47.23M | Net income 2025 * | -65M -69.78M | EV / Sales 2024 * | -4.84 x |
Net cash position 2024 * | 3.43B 3.69B | Net cash position 2025 * | 3.13B 3.36B | EV / Sales 2025 * | -4.21 x |
P/E ratio 2024 * |
-28.5
x | P/E ratio 2025 * |
-20.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.64% |
Latest transcript on Galapagos NV
Managers | Title | Age | Since |
---|---|---|---|
Paulus Stoffels
CEO | Chief Executive Officer | 62 | 22-03-31 |
Thad Huston
DFI | Director of Finance/CFO | 54 | 23-05-31 |
Investor Relations Contact | - | 20-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Dickinson
BRD | Director/Board Member | 54 | Mar. 26 |
Jérôme Contamine
BRD | Director/Board Member | 66 | 22-04-25 |
Simon Sturge
BRD | Director/Board Member | 65 | 23-09-18 |
1st Jan change | Capi. | |
---|---|---|
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |